Meridian Bioscience (VIVO) Tops Q1 EPS by 10c; Offers 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $1.60 -27.6%
Financial Fact:
Total operating expenses: 20.83M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Total operating expenses: 20.83M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $88.3 million versus the consensus estimate of $70.29 million.
GUIDANCE:
Meridian Bioscience sees FY2022 EPS of $1.10-$1.30, versus the consensus of $1.04. Meridian Bioscience sees FY2022 revenue of $315-330 million, versus the consensus of $288 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- LTC Properties (LTC) Tops Q3 EPS by 22c
- Innospec (IOSP) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
